News summary

Leqembi pen subcutaneous formulation available in Japan

Source: Longevity Technology • Published: 16 Nov 2026, 11:56

Summarized by Masters of Longevity from Longevity Technology.

Eisai and Biogen launched a subcutaneous Leqembi pen in Japan with reimbursement.

Leqembi pen subcutaneous formulation available in Japan
Key Takeaways
  • Eisai and Biogen launched the Leqembi Pen on November 12, 2026.
  • Japan approved the subcutaneous formulation on September 16, 2026.
  • The pen was added to Japan's National Health Insurance drug list.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.